336 related articles for article (PubMed ID: 18929796)
21. Utility of semiquantitative polymerase chain reaction for Epstein-Barr virus to measure virus load in pediatric organ transplant recipients with and without posttransplant lymphoproliferative disease.
Allen U; Hebert D; Petric M; Tellier R; Tran D; Superina R; Stephens D; West L; Wasfy S; Nelson S
Clin Infect Dis; 2001 Jul; 33(2):145-50. PubMed ID: 11418872
[TBL] [Abstract][Full Text] [Related]
22. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
[TBL] [Abstract][Full Text] [Related]
23. Association between elevated whole blood Epstein-Barr virus (EBV)-encoded RNA EBV polymerase chain reaction and reduced incidence of acute lung allograft rejection.
Ahya VN; Douglas LP; Andreadis C; Arnoldi S; Svoboda J; Kotloff RM; Hadjiliadis D; Sager JS; Woo YJ; Pochettino A; Schuster SJ; Stadtmauer EA; Tsai DE
J Heart Lung Transplant; 2007 Aug; 26(8):839-44. PubMed ID: 17692789
[TBL] [Abstract][Full Text] [Related]
24. Slc11a1 (formerly Nramp1) polymorphisms and susceptibility to post-transplant lymphoproliferative disease following pediatric liver transplantation.
Barshes NR; Lee TR; Goss JA; Goodpastor SE; Huls MH; Rooney CM; Karpen SJ; Wyllie S
Transpl Infect Dis; 2006 Jun; 8(2):108-12. PubMed ID: 16734634
[TBL] [Abstract][Full Text] [Related]
25. A Scheduled Program of Molecular Screening for Epstein-Barr Virus Decreases the Incidence of Post-transplantation Lymphoproliferative Disease in Pediatric Liver Transplantation.
Soriano-López DP; Alcántar-Fierros JM; Hernández-Plata JA; González-Jorge AL; Velázquez-Ramos S; Flores-Hernández MA; Fuentes V; Castañeda P; Nieto J; Sánchez JL; López B; Valencia-Mayoral P; Varela-Fascinetto G
Transplant Proc; 2016 Mar; 48(2):654-7. PubMed ID: 27110023
[TBL] [Abstract][Full Text] [Related]
26. OKT3 and ganciclovir treatments are possibly related to the presence of Epstein-Barr virus in serum after liver transplantation.
Barkholt L; Linde A; Falk KI
Transpl Int; 2005 Jul; 18(7):835-43. PubMed ID: 15948864
[TBL] [Abstract][Full Text] [Related]
27. Timing of Epstein-Barr virus acquisition and the course of posttransplantation lymphoproliferative disorder in children.
Wu JF; Ho MC; Ni YH; Chen HL; Lu CY; Hsu HY; Lee PH; Chang MH
Transplantation; 2009 Mar; 87(5):758-62. PubMed ID: 19295323
[TBL] [Abstract][Full Text] [Related]
28. The role of valacyclovir on Epstein-Barr virus viral loads in pediatric liver transplantation patients.
Ozçay F; Arslan H; Bilezikçi B; Sevmiş S; Moray G; Haberal M
Transplant Proc; 2009 Sep; 41(7):2878-80. PubMed ID: 19765462
[TBL] [Abstract][Full Text] [Related]
29. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection.
Lee TC; Goss JA; Rooney CM; Heslop HE; Barshes NR; Caldwell YM; Gee AP; Scott JD; Savoldo B
Clin Transplant; 2006; 20(6):689-94. PubMed ID: 17100717
[TBL] [Abstract][Full Text] [Related]
30. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder.
Humar A; Hébert D; Davies HD; Humar A; Stephens D; O'Doherty B; Allen U
Transplantation; 2006 Mar; 81(6):856-61. PubMed ID: 16570008
[TBL] [Abstract][Full Text] [Related]
31. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease.
Meerbach A; Wutzler P; Häfer R; Zintl F; Gruhn B
J Med Virol; 2008 Mar; 80(3):441-54. PubMed ID: 18205222
[TBL] [Abstract][Full Text] [Related]
32. Screening for PTLD in lung and heart-lung transplant recipients by measuring EBV DNA load in bronchoalveolar lavage fluid using real time PCR.
Michelson P; Watkins B; Webber SA; Wadowsky R; Michaels MG
Pediatr Transplant; 2008 Jun; 12(4):464-8. PubMed ID: 18466434
[TBL] [Abstract][Full Text] [Related]
33. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience.
Kogan-Liberman D; Burroughs M; Emre S; Moscona A; Shneider BL
J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):445-9. PubMed ID: 11698761
[TBL] [Abstract][Full Text] [Related]
34. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
McDiarmid SV; Jordan S; Kim GS; Toyoda M; Goss JA; Vargas JH; Martín MG; Bahar R; Maxfield AL; Ament ME; Busuttil RW
Transplantation; 1998 Dec; 66(12):1604-11. PubMed ID: 9884246
[TBL] [Abstract][Full Text] [Related]
35. Post-transplant lymphoproliferative disease in pediatric lung transplant recipients: recent advances in monitoring.
Elidemir O; Kancherla BS; Schecter MG; McKenzie ED; Morales DL; Heinle JS; Mallory GB
Pediatr Transplant; 2009 Aug; 13(5):606-10. PubMed ID: 19017289
[TBL] [Abstract][Full Text] [Related]
36. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
Younes BS; McDiarmid SV; Martin MG; Vargas JH; Goss JA; Busuttil RW; Ament ME
Transplantation; 2000 Jul; 70(1):94-9. PubMed ID: 10919581
[TBL] [Abstract][Full Text] [Related]
37. Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases.
Babel N; Gabdrakhmanova L; Hammer M; Rosenberger C; Oppert M; Volk HD; Reinke P
Transpl Infect Dis; 2005; 7(3-4):133-6. PubMed ID: 16390402
[TBL] [Abstract][Full Text] [Related]
38. The changing face of post-transplant lymphoproliferative disease in the era of molecular EBV monitoring.
Kerkar N; Morotti RA; Madan RP; Shneider B; Herold BC; Dugan C; Miloh T; Karabicak I; Strauchen JA; Emre S
Pediatr Transplant; 2010 Jun; 14(4):504-11. PubMed ID: 20070559
[TBL] [Abstract][Full Text] [Related]
39. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment.
Guthery SL; Heubi JE; Bucuvalas JC; Gross TG; Ryckman FC; Alonso MH; Balistreri WF; Hornung RW
Transplantation; 2003 Apr; 75(7):987-93. PubMed ID: 12698085
[TBL] [Abstract][Full Text] [Related]
40. Posttransplant lymphoproliferative disorders in transplant recipients.
Timurağaoğlu A; Uğur-Bilgin A; Colak D; Tuncer M; Gölbaşi I; Hazar V; Kiliçarsłan B; Undar L; Demirbaş A
Transplant Proc; 2006 Mar; 38(2):641-5. PubMed ID: 16549195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
